Background: By using array comparative genomic hybridization (CGH), the increased copy number of CYP24 (which encodes vitamin D 24-hydroxylase) at 20q13.2 was previously reported, leading to the identification of CYP24 as a candidate oncogene in breast cancer. CYP24 leads to abrogate growth control mediated by vitamin D.
Introduction
Chromosomal location 20q13.2 is particularly attractive because aberrations in this region occur in various cancers. Increased copy number was observed in 40% of breast cancer cell lines [1] , colon cancer [2] , pancreatic cancer [2] , and head and neck cancer [3] . The amplification of chromosome 20q in cultured cells is associated with progressing tumor phenotypes, including immortalization and genomic instability, therefore identification of genes in 20q has been a common goal for numerous researchers. Albertson et al. identified the putative oncogenes ZNF217 and CYP24 (encoding vitamin D 24-hydroxylase) in 20q13.2, within a 2 Mb region of recurrent aberrations that occur in breast cancer, by using array comparative genomic hybridization (CGH) [4] . CYP24 is distally located to the putative oncogene ZNF217, and thus is a candidate gene itself. As the overexpression of CYP24 in breast cancer tissue has been reported, we investigated the clinical significance of CYP24 overexpression in other human cancers, especially in esophageal cancer which is known to be one of the malignant tumors associated with poor prognosis.
The known function of CYP24, i.e. the limitation of the biological activity of the vitamin D signaling system [5] [6] [7] , supports its candidacy. In fact, CYP24 overexpression is likely to lead to abrogation of growth control mediated by vitamin D in breast cancer cases. We therefore focused on whether the significant relationship between CYP24 and VDR expression was observed in esophageal cancer in vivo and in vitro. The result may be one of the clues towards clarifying the mechanism of CYP24 in promoting malignant behavior in esophageal cancer. This is the first report to disclose the clinical significance of the expression of the newly identified candidate oncogene CYP24 and its relationship with VDR gene in esophageal cancer.
Materials and methods

Surgical specimens and cancer cell lines
Tumors and the corresponding normal specimens from 35 male and seven female patients with esophageal cancer were made available for this study by the Department of Surgery, Saitama Cancer Center, from 1993 to 1996. The centers of the cancer and normal tissues were extracted from surgically resected specimens and pathologically diagnosed. Five cases were treated with carboplatin, cisplatin or vinblastine as a postoperative chemotherapy. All samples were immediately stored at -80°C until utilized. The average patient age was 62.1 years (range 40-82 years). The data of several clinicopathological variables, such as sex, depth of tumor invasion, lymph node metastasis, lymph vessel permeation, vascular vessel permeation, disease stage and overall survival, were completely reviewed for all patients (Table 1) . There were 39 cases of squamous cell carcinoma, two cases of basal squamous cell carcinoma and one case of adenocarcinoma of the esophagus.
We examined the following esophageal cancer cell lines: TE7, TE12, TE13, KY70, KY110, KY150 and KY180 [8, 9] . TE12, TE13, KY70, KY110, KY150 and KY180 were derived from squamous cell carcinoma, while TE7 was from adenocarcinoma.
cDNA preparation from tissue specimens
Total RNA was extracted from ∼500 mg of each resected specimen according to the method of Chomczynski et al. All samples were treated in Eppendorf tubes (Eppendorf, Germany) and handled with gloves to avoid contamination with RNAase. To ensure that the RNA was not degraded, 2 µg of RNA were run on an agarose gel and stained with ethidium bromide to look for intact 28S and 18S RNAs. The 2 µg of RNA was reverse transcribed into cDNA using oligo-dT primers according to the manufacturer's protocol (Gibco-BRL, Japan).
Semi-quantitative analysis of CYP24 and VDR
The primer sequences of CYP24, VDR [4] and glyceraldehyde-3-phosphatedehydrogenase (GAPDH), which was utilized as an internal control, are described elsewhere [10] .
In brief, CYP24 and VDR cDNA amplification was performed in 25 µl of 10× PCR buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl 2 , 1% Triton X-100), 25 mM dNTP (dATP, dCTP, dGTP and dTTP; 100 mM each), 10 pmol each of the CYP24 and VDR primers and 1 U Taq DNA polymerase (Promega, Madison, WI). The reactions were subjected to 24 cycles for 1 min at 94°C, 1 min at 60°C and 90 s at 72°C in a 9600 thermal cycler (Perkin-Elmer Roche, Japan). GAPDH amplification was performed as described previously [10] . Amplified DNA fragments were separated on a 1.5% agarose gel con- 
The induction of CYP24 expression and the MTT assay
We examined TE12 as a representative cell line that induced CYP24 expression and diminished VDR expression. On the other hand, KY110 was selected as a non-responding cell to the administration of 25(OH)D 3 . Both cell lines were examined three times to compare cell growth rate using the 3-(4, 5-dimethylthiazol-2-y)-2, 5-diphenyltetrazolium bromide (MTT) assay system. Both cell lines were cultured in RPMI-1640 supplemented with 10% FCS. Approximately 8.5 × 10 6 cells were washed twice with PBS and the medium was replaced with RPMI-1640 supplemented with 1% BSA. The inducer, 10 µM 25(OH)D 3 , and the antioxidant, 100 µM 1.2-dianilinoethane (Sigma, Tokyo) with ethanol as a solvent were added, and the cells were incubated for 24 h. We performed MTT assay for both cells as follows. After the incubation at 37°C for 8 days in a humid 5% CO 2 atmosphere, the plates were centrifuged at 700 g, the supernatants were discarded and 20 µl of MTT solution (10 µM) was added to all the wells according to the manufacturer's protocol for the Cell Proliferation Kit I (Roche, Tokyo, Japan). After incubation for 4 h, 150 µl of stop solution was added to all the wells for extracting the formazan formed by MTT. The absorbance of formazan in each well was measured using a microplate reader (Bio-Rad, Japan) at a test wavelength of 570-650 µm; results were given as optimal density per milligram of protein (OD/mg protein).
Results
CYP24 and VDR expression in tumor and normal tissues
The semi-quantitative measurements of CYP24 expression in tumor and the corresponding normal tissues with the appropriate RT-PCR cycles are shown in Figure 1 . CYP24 had not previously been implicated in esophageal cancer, however a relatively higher expression of CYP24 was observed in tumor tissues as compared with normal tissues in this study. In addition, CYP24 is upregulated in malignant tissues (Figure 2 ). This observation led us to focus on the clinicopathological significance of CYP24 expression and its possible role in esophageal cancer progression.
CYP24 expression in cancer tissues was then compared with that of the corresponding normal esophageal tissues. The average T:N ratio of CYP24 is 1.98 (range 0.1-21.8). In clinicopathological features, the higher expression of CYP24 was observed in cases with deep invasion of tumor, high lymphatic permeation and high venous permeation; however, there was no statistical significance among them (Table 1 ). In contrast, the average VDR expression is 1.16, ranging from 0.1 to 15. Lower expression of the VDR gene was observed in five of seven cases (70%) with poorly differentiated squamous cell cancer, 15 of 27 cases (56%) of high lymph node metastases, and 16 of 26 cases (62%) of high lymphatic permeation, however there was no statistical significant correlation between these clinicopathological factors and VDR expression (Table 1) . Interestingly, the overall survival rate was significantly higher in 25 cases of lower CYP24 expression than 17 cases of higher CYP24 expression (P <0.05). On the other hand, 23 cases of low VDR expression had a relatively poorer prognosis than 19 cases of high VDR expression; however there was no statistical significance ( Figure 3) .
The relationship between CYP24 and VDR in esophageal cancer cases and esophageal cancer cell lines Table 2 shows the inverse correlation between expression of CYP24 and VDR in 42 esophageal cancer cases. In 17 cases of high expression of the CYP24 gene, 13 (76%) cases showed lower VDR gene expression, while in 25 cases of low CYP24 expression, 15 (60%) cases indicated high VDR gene expression; there was a significant correlation between them. However, determination of the precise relationship between CYP24 and VDR genes certainly required larger numbers of cases.
In Figure 4 , the induction of CYP24 expression was observed in TE7, TE12, KY70, KY150 and KY180 by 25(OH)D 3 . TE13 originally expressed CYP24 in the corresponding parent cells, and KY110 showed neither CYP24 nor VDR expression. In contrast, VDR expression was reduced in TE12, TE13 and KY70. We therefore selected TE12 as a representative cell line with increased CYP24 expression as well as diminished VDR expression, while KY110 was used for further experiments as a non-responding cell to the administration of 25(OH)D 3 .
Comparison of cell growth between CYP24-induced and VDR-reduced cells (TE12) and a non-responding cell (KY110)
In Figure 5 , cell growth of the TE12 cell with CYP24 induction gradually increased more significantly than either the control or 
Discussion
Vitamin D is considered to protect against malignancies by dietary intake in colorectal cancer [13, 14] and breast cancer [6] . As in the present study of esophageal cancer, Launoy et al. identified that vitamin D is one of the independent protective factors among dietary factors influencing the risk of this malignancy [15] . Therefore, the abrogating vitamin D-mediated growth control is believed to play a protective role in the pathogenesis of solid cancer. CYP24, a vitamin D hydroxylase, has been recognized as one of the regulators of the biological effect of the vitamin D signaling system [16] . Miller et al. reported that growth inhibition of human prostatic cancer cells was correlated not only with the number of vitamin receptors per cell, but also with the inverse proportion of the 24-hydroxylase activity [17] .
In this study, we have shown that higher CYP24 expression and/ or lower VDR expression indicates a poor prognosis, deep invasion of tumor, increased incidence of high lymphatic permeation or venous permeation. We consider that up-regulated CYP24 expression in cancer tissues and/or down-regulated VDR expression may play important roles in the progression of esophageal cancer rather than having carcinogenic activity on esophageal cancer. Interestingly, we have also clarified that vitamin D expression is inversely correlated with CYP24 expression, therefore we speculate that the disruption of the vitamin D regulating system may promote esophageal cancer progression, which is caused by the overexpression of the putative oncogene CYP24. As shown in Figure 5 , growth of esophageal cancer cells increased under the high expression of CYP24 and diminished expression of VDR; however, KY110 cells with neither CYP24 nor VDR expression showed no change after the administration of 25(OH)D 3 . Therefore, the present results also suggest that the disruption of the vitamin D regulating system with diminished expression of the VDR gene due to overexpression of the oncogene CYP24 promote or enhance the malignant potential of esophageal cancer.
We are the first in the world to have disclosed the significance of overexpression of the candidate oncogene CYP24 in esophageal cancer. As stated above, CYP24 is considered a prognostic factor in esophageal cancer, and we expect that it can be used as a powerful new molecular target in gene therapy, to either cure or protect against esophageal cancer. 
